Market Overview

Paul Chew, MD Joins Phesi as Chief Medical Officer and Board Member

Share:

Strengthening of Leadership Team Coincides with Phesi's Expansion of
its Clinical Development Services Business, which Enhances Clinical
Trial Efficiency and Cost-Effectiveness

Phesi, a technology-enabled, data-driven provider of premier clinical
development services, today announced the addition of Paul Chew, MD, as
its Chief Medical Officer (CMO). Dr. Chew also joins the Phesi Board
of Directors
, which was expanded in 2017 by the appointments of
Annalisa Jenkins, MBBS, FRCP, and Steve Arlington, PhD. Phesi leverages
the industry's most comprehensive clinical trials database and
predictive analytics tools to help trial sponsors make timely and
informed decisions, and to expedite drug development. Dr. Chew and the
distinguished Board will help guide the company as it continues to
expand its work with global life sciences companies.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180424005158/en/

"I am thrilled to have Dr. Chew join our growing team as we seek to
enhance industry use of our unique clinical development platform," said
Gen Li, PhD, MBA, founder and president of Phesi. "His guidance, along
with that of our other Board members, will help Phesi optimize our
service offerings, which are designed to enable researchers to complete
clinical trials on time and within budget."

"Phesi is the pharmaceutical industry's best-kept secret in that its
rigorous scientific approach enhances the efficiency and
cost-effectiveness of clinical trials, which currently take too long and
are too expensive," said Dr. Chew. "Phesi applies knowledge derived from
observation and experimentation to inform new clinical programs or
rescue ongoing ones, integrating all the moving pieces from early
development planning through to Phase III, making Phesi a game-changer
in the life sciences space."

Over his distinguished career, Dr. Chew, a cardiologist by training, has
held several executive positions at major pharmaceutical companies
including Bristol-Myers Squibb and Sanofi, where he served as senior
vice-president, global chief medical officer, and U.S. R&D head. He was
most recently the CMO of Omada Health, where he and his team launched
the largest randomized clinical trial to date in digital therapeutics.
Dr. Chew serves as Medical Trustee on the U.S. Pharmacopeia Board of
Trustees. He spent more than 20 years at the Johns Hopkins University
and School of Medicine, where he received his undergraduate education,
and medical training, and where he held various faculty positions.

Phesi's granular and dynamic clinical trials database contains more
information and records than any other source, including
clinicaltrials.gov. Using proprietary methods, Phesi mines its database
to consolidate real-time information from millions of data points to
reduce trial start-up time, lower costs, minimize the number of protocol
amendments, determine the appropriate number of trial sites, and
accelerate time to launch. Phesi's unique drug development technology
platform can cut clinical trial design analysis timelines from 18-24
months to just 3-4 weeks, and reduce trial costs by 20%-40%.

Despite increasingly high societal demand to accelerate drug development
and approval timelines, clinical trials are still largely managed by
"old school" approaches, and therefore remain challenged by significant
delays, ballooning costs, and irreproducible outcomes. According to the
Tufts Center for the Study of Drug Development, the cost of bringing
just one drug to market currently exceeds $2.5 billion.

Phesi offers smart technology with simple solutions for complex issues,
removing common barriers to effective clinical trials and placing novel
therapies into the hands of patients faster. Now in its 11th
year in business, Phesi recently completed full automation of all of its
systems, as well as a complete re-branding with a fresh, new logo and an
updated website: www.phesi.com.

More About Phesi

Founded in 2007 as Pharmaceutical Pipeline Enhancement Strategies, Phesi
is a dynamic, data-driven drug development company, providing
comprehensive clinical development services for life sciences companies
around the world. Phesi's integrated service offerings cover the entire
clinical development process: from development planning and indication
assessment to protocol evaluation, site selection, and trial
implementation management.

Phesi has the industry's most comprehensive and dynamic clinical trials
database and predictive analytics tools, consisting of more than 213,000
completed clinical trials, 604,000 completed clinical research projects,
and over 1.6 million investigator records.

The leadership team at Phesi is driving the future of pharmaceutical
R&D, offering unique perspectives on the optimal role of digital
technology, the importance of building service organizations around new
technology, and an overall understanding of the transformation that
needs to happen to improve clinical development.

For more information please visit www.phesi.com.
Follow Phesi on LinkedIn
and Twitter.

View Comments and Join the Discussion!